Shots:
- Agilent Technologies has received the US FDA approval for its MMR IHC Panel pharmDx (Dako Omnis) as a companion diagnostic (CDx) test for colorectal cancer
- Agilent & BMS partnered to develop the MMR IHC Panel pharmDx (Dako Omnis) to identify dMMR colorectal cancer pts eligible for Opdivo monotx. or Opdivo + Yervoy treatment
- The MMR IHC Panel pharmDx (Dako Omnis) is an immunohistochemical (IHC) test for detecting loss of function in any of the four MMR proteins ((MLH1, PMS2, MSH2, & MSH6) in formalin-fixed paraffin-embedded colorectal cancer tissue, approved exclusively for use with the Agilent Dako Omnis automated staining solution
Ref: Businesswire | Image: Agilent | Press Release
Related News:- Myra Vision Receives FDA Conditional IDE Approval for Calibreye TGT System to Treat Glaucoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
